Duaklir and Brimica are brand names for a fixed-dose combination medication that contains aclidinium bromide.
Aclidinium bromide is a key component in certain inhaled medications primarily used for the management of chronic obstructive pulmonary disease (COPD). It acts as a long-acting muscarinic antagonist (LAMA), helping to relax the muscles around the airways in the lungs, making it easier to breathe.
Medications Containing Aclidinium Bromide
While aclidinium bromide can exist as a single-agent medication (e.g., Tudorza Pressair in some regions), it is also commonly found in combination with other bronchodilators to enhance its therapeutic effects. The provided reference highlights a specific combination:
- Aclidinium bromide/formoterol: This is a combination of aclidinium bromide (a LAMA) and formoterol (a long-acting β2 agonist, LABA). This combination provides a dual bronchodilator effect, which is beneficial for patients with COPD.
Brand Names
The combination of aclidinium bromide and formoterol is sold under the following brand names:
| Medication Combination | Brand Names | Primary Use | Components |
|---|---|---|---|
| Aclidinium bromide/Formoterol | Duaklir | Management of COPD | Aclidinium bromide (LAMA), Formoterol (LABA) |
| Aclidinium bromide/Formoterol | Brimica | Management of COPD | Aclidinium bromide (LAMA), Formoterol (LABA) |
These medications are administered via inhalation and are specifically designed to provide sustained bronchodilation, improving lung function and reducing symptoms in individuals with COPD.
